Outlook Therapeutics Expands Commercial Team with Appointment of Senior Vice President of Commercial Operations
Joel Prieve brings nearly 20 years of commercial operations expertise and proven track record in…
Joel Prieve brings nearly 20 years of commercial operations expertise and proven track record in…
INT301 Met Safety Goals Across Four Dose Levels in Cohort 1 Patient Treatment Now Ongoing…
Oslo, Norway, 8 February 2022 Vistin Pharma ASA will release its fourth quarter 2021 results…
No additional clinical work required; NDA resubmission anticipated in Q3 2022 NEW YORK, Feb. 08,…
– Ovid to License Gaboxadol to Healx – – Healx to Explore Gaboxadol in Combination…
BELTSVILLE, Md., Feb. 08, 2022 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical…
GARDEN CITY, N.Y., Feb. 08, 2022 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ: XAIR), a…
REDWOOD CITY, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO),…
HOUSTON, Feb. 08, 2022 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical…
Incidence and Severity of Post-Surgical Intraabdominal Adhesions following Bowel Resection Surgery and Treatment with Enteral…
SOUTH SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) — Frontier Medicines Corporation, a precision…
GelStat Corporation Has Been Qualified by the SEC for a Regulation A+ Public Offering STUART,…
SOUTH SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage…
CAMBRIDGE, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”)…
Completed enrollment ahead of schedule in second Phase 3 FDA registration trial for Nyxol in…
Highlights: Seven subjects in cohort three intravenously dosed; RECCE® 327 at 500mg indicating to be…
Friday, February 11th 2012 – 12 pm EST / 6 pm CET Featuring Dr. Joanna…
TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) — Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia…
Oculis appoints Dr. Bastian Dehmel as Chief Development Officer Former Amgen Global Development Leader/OxThera CMO…
JENA, Germany, Feb. 08, 2022 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical…